News Conference News TCT 2018 Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos Michael O'Riordan October 02, 2018
News Daily News ‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients Michael O'Riordan August 23, 2018
News Daily News ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights Michael O'Riordan July 10, 2018
News Conference News EuroPCR 2018 ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics Michael O'Riordan May 31, 2018
News Conference News EuroPCR 2018 Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions Michael O'Riordan May 23, 2018
News Conference News EuroPCR 2018 FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis Michael O'Riordan May 22, 2018
Presentation Intravascular Coronary Imaging and Physiology 2018 PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA Presenter: Rasha Al-Lamee May 05, 2018
Podcast TCTMD Talking Points ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease May 02, 2018
News Features ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging Michael O'Riordan March 23, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018